Company Profile
Enliven Therapeutics Stock Price, News & Analysis
- Ticker:
- ELVN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
52.73 USD (-0.41%)
Close
Last updated: July 27, 2026
2.16B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ELVN closed down 0.41% at $52.73. No new same-company headline was identified in the current news window.
Company overview
Business overview
Enliven Therapeutics is an oncology company focused on targeted therapies and precision cancer medicine. Its development strategy emphasizes genetically defined cancers and differentiated molecules.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Enliven sits in specialty oncology biotechnology.
Business Model Characteristics
The business depends on clinical data, compound differentiation, and the potential to build a focused oncology franchise.
Position Within the Biotechnology Landscape
Enliven is a small-cap oncology catalyst name whose valuation can move sharply on data quality.
Future catalysts
Enliven is now very clearly a CML company around ELVN-001. The positive Phase 1b data, the planned Phase 3 ENABLE-2 start, and the broader regulatory work all make the next stretch important because they tell us whether the asset can keep moving toward a more defined launch path.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Enliven Therapeutics (ELVN)?
Enliven Therapeutics (ELVN) most recently closed at 52.73 USD, a -0.41% move versus the previous session.
What is the market cap of Enliven Therapeutics (ELVN)?
Enliven Therapeutics currently has a market capitalization of 2.16B USD on BioPharmSignal.
What does Enliven Therapeutics do?
Enliven Therapeutics is an oncology company focused on targeted therapies and precision cancer medicine. Its development strategy emphasizes genetically defined cancers and differentiated molecules.
On which exchange is ELVN stock listed?
Enliven Therapeutics (ELVN) is associated with NASDAQ, United States, Biopharma.
What is ELVN-001?
Enliven is now very clearly a CML company around ELVN-001.
Which conditions is Enliven Therapeutics targeting with ELVN-001?
Enliven Therapeutics is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Enliven Therapeutics describe recent progress with ELVN-001?
Enliven is now very clearly a CML company around ELVN-001.
What is ENABLE-2?
The positive Phase 1b data, the planned Phase 3 ENABLE-2 start, and the broader regulatory work all make the next stretch important because they tell us whether the asset can keep moving toward a more defined launch path.